Início › Câncer Endometrial › Rhode Island › Providence
Ensaios clínicos de Câncer Endometrial em Providence, RI
14 estudos para Câncer Endometrial estão buscando participantes em locais em Providence e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecrutandoFase 2
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecrutandoFase 1
- Women and Infants Hospital, Providence
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecrutandoFase 3
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecrutandoFase 2
- Women and Infants Hospital, Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecrutandoFase 2
- Women and Infants Hospital, Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecrutandoFase 3
- Women & Infants Hospital ( Site 5003), Providence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecrutandoFase 1
- Women & Infants Hospital of Rhode Island, Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecrutandoFase 3
- Research Site, Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecrutandoFase 1/2
- Research Site, Providence
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecrutandoFase 2
- Women & Infants Hospital, Providence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecrutandoFase 1/2
- Women and Infants Hospital of Rhode Island, Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RecrutandoFase 2
- Women & Infants Hospital, Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RecrutandoFase 1/2
- Women & Infants Hospital, Providence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Providence
Ensaios de Câncer Endometrial em outras cidades
- Houston, TX68 estudos
- New York City, NY52 estudos
- Boston, MA50 estudos
- Arlington, VA39 estudos
- Nashville, TN38 estudos
- Los Angeles, CA34 estudos
- St. Louis, MO29 estudos
- Philadelphia, PA28 estudos
- San Antonio, TX27 estudos
- Chicago, IL25 estudos
- Columbus, OH25 estudos
- Queens, NY25 estudos
Outros estudos em Providence
- Câncer de Ovário15 estudos
- Obesidade14 estudos
- Câncer de Pulmão de Não Pequenas Células12 estudos
- Câncer (todos os tipos)12 estudos
- Doença de Crohn12 estudos
- Colite ulcerativa11 estudos
- Câncer de Mama11 estudos
- Leucemia Mieloide Aguda10 estudos
- Câncer Metastático9 estudos
- Sobrepeso9 estudos
- Doença de Alzheimer8 estudos
- Transtorno por Uso de Álcool (AUD)8 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.